62168 Federal Register / Vol. 79, No. 200 / Thursday, October 16, 2014 / Notices

93.846–93.878, 93.892, 93.893, National DEPARTMENT OF HEALTH AND Manager, Office of Technology Transfer, Institutes of Health, HHS) HUMAN SERVICES National Institutes of Health, 6011 Dated: October 9, 2014. Executive Boulevard, Suite 325, National Institutes of Health Carolyn Baum, Rockville, MD 20852–3804; Telephone: (301) 435–4632; Facsimile: (301) 402– Program Analyst, Office of Federal Advisory Prospective Grant of Exclusive Option 0220; Email: [email protected]. Committee Policy. License: The Development of a Single [FR Doc. 2014–24601 Filed 10–15–14; 8:45 am] Domain Human Anti-Mesothelin SUPPLEMENTARY INFORMATION: This BILLING CODE 4140–01–P Monoclonal Antibody for the Treatment invention concerns a monoclonal of Human Cancers antibody and methods of using the AGENCY: National Institutes of Health, antibody for the treatment of DEPARTMENT OF HEALTH AND HHS. mesothelin-expressing cancers, HUMAN SERVICES including , lung cancer, ACTION: Notice. and . National Institutes of Health SUMMARY: This is notice, in accordance The specific antibody covered by this with 35 U.S.C. 209 and 37 CFR part 404, technology is designated SD1, which is National Research that the National Institutes of Health, a single domain, fully human Institute; Notice of Closed Meeting Department of Health and Human monoclonal antibody against Services, is contemplating the grant of Pursuant to section 10(d) of the mesothelin. an exclusive start-up option license to Federal Advisory Committee Act, as Mesothelin is a cell surface antigen practice the inventions embodied in that is preferentially expressed on amended (5 U.S.C. App.), notice is U.S. Patent Application 61/706,396 certain types of cancer cells. The SD1 hereby given of the following meeting. entitled ‘‘Mesothelin Antibodies And The meeting will be closed to the Methods For Eliciting Potent Antitumor antibody can selectively bind to these public in accordance with the Activity’’ [HHS Ref. E–236–2012/0–US– cancer cells and induce cell death while provisions set forth in sections 01], PCT Application PCT/US2013/ leaving healthy, essential cells 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 059883 entitled ‘‘Mesothelin Antibodies unharmed. This can result in an as amended. The grant applications and And Methods For Eliciting Potent effective therapeutic strategy with fewer the discussions could disclose Antitumor Activity’’ [HHS Ref. E–236– side effects due to less non-specific confidential trade secrets or commercial 2012/0–PCT–02], and all related killing of cells. property such as patentable material, continuing and foreign patents/patent The prospective exclusive start-up and personal information concerning applications for the technology family, option license will be royalty bearing individuals associated with the grant to H2Bio, Inc. The patent rights in these and will comply with the terms and applications, the disclosure of which inventions have been assigned to and/or conditions of 35 U.S.C. 209 and 37 CFR would constitute a clearly unwarranted exclusively licensed to the Government Part 404. The prospective exclusive invasion of personal privacy. of the United States of America. start-up option license may be granted The prospective exclusive start-up unless the NIH receives written Name of Committee: Center for Inherited option licensed territory may be evidence and argument that establishes Disease Research Access Committee. worldwide, and the field of use may be that the grant of the license would not Date: October 29, 2014. limited to: Time: 10:00 a.m. to 11:00 a.m. be consistent with the requirements of The use of SD1-serine protease Agenda: To review and evaluate grant 35 U.S.C. 209 and 37 CFR Part 404 immunoconjugates for the treatment of within fifteen (15) days from the date of applications. mesothelioma, pancreatic cancer, ovarian Place: National Institutes of Health, 5635 cancer and lung , including this published notice. Fishers Lane, Bethesda, MD 20892 combination therapies using the SD1-serine Complete applications for a license in (Telephone Conference Call). protease immunoconjugate, wherein the the field of use filed in response to this Contact Person: Ken Nakamura, Ph.D., serine protease is Granzyme B (GrB) or a notice will be treated as objections to Scientific Review Officer, Scientific Review Derivative thereof. the grant of the contemplated exclusive Branch, National Human Genome Research Upon the expiration or termination of start-up option license. Comments and Institute, National Institutes of Health, 5635 the exclusive start-up option license, objections submitted to this notice will Fishers Lane, Suite 4076, MSC 9306, H2Bio, Inc. will have the exclusive right Rockville, MD 20852, 301–402–0838. not be made available for public to execute an exclusive inspection and, to the extent permitted This notice is being published less than 15 commercialization license which will by law, will not be released under the days prior to the meeting due to the timing supersede and replace the exclusive limitations imposed by the review and Freedom of Information Act, 5 U.S.C. start-up option license with no greater 552. funding cycle. field of use and territory than granted in (Catalogue of Federal Domestic Assistance the exclusive start-up option license. Dated: October 8, 2014. Program Nos. 93.172, Human Genome DATES: Only written comments and/or Richard U. Rodriguez, Research, National Institutes of Health, HHS) applications for a license which are Director, Division of Technology Development Dated: October 10, 2014. received by the NIH Office of and Transfer, Office of Technology Transfer, David Clary, Technology Transfer on or before National Institutes of Health. October 31, 2014 will be considered. [FR Doc. 2014–24501 Filed 10–15–14; 8:45 am] Program Analyst, Office of Federal Advisory Committee Policy. ADDRESSES: Requests for copies of the BILLING CODE 4140–01–P [FR Doc. 2014–24605 Filed 10–15–14; 8:45 am] patent application, inquiries, comments, and other materials relating to the BILLING CODE 4140–01–P contemplated exclusive license should be directed to: David A. Lambertson, Ph.D., Senior Licensing and Patenting

VerDate Sep<11>2014 17:19 Oct 15, 2014 Jkt 235001 PO 00000 Frm 00077 Fmt 4703 Sfmt 9990 E:\FR\FM\16OCN1.SGM 16OCN1 asabaliauskas on DSK5VPTVN1PROD with NOTICES